Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Robert C. Schriver"'
Autor:
Ernest S Harpur, Devan V. Mehrotra, Eileen C King, Manfred Oster, Jesse A. Berlin, Robert C Schriver, Juergen Kuebler, David B. Hall, Hongliang Shi, Zhengqing Li, Brenda J. Crowe, Jane B Porter, Nancy C. Santanello, Douglas J. Watson, H. Amy Xia, George Rochester, Stephen L Lin
Publikováno v:
Clinical Trials. 6:430-440
Background The Safety Planning, Evaluation and Reporting Team (SPERT) was formed in 2006 by the Pharmaceutical Research and Manufacturers of America. Purpose SPERT’s goal was to propose a pharmaceutical industry standard for safety planning, data c
Publikováno v:
Clinical trials (London, England). 8(2)
Background In 2009, the Safety Planning, Evaluation and Reporting Team gave detailed recommendations for a well-planned and systematic approach for safety data collection and analysis. Important aspects of this approach included regular reviews of ag
Publikováno v:
Clinical Trials. 6:445-445
Publikováno v:
The Journal of Clinical Pharmacology. 21:106-109
A controlled-release lithium carbonate tablet was compared to an immediate-release lithium carbonate capsule in normal volunteers. These crossover studies at steady state showed that the tablet produced a smoother serum curve than the capsule with no
Autor:
Karl E. Peace, Robert C. Schriver
Publikováno v:
Journal of chronic diseases. 40(1)
This paper presents at an instructive level detailed design, decision and computational aspects of p-values and power for clinical trials in which interim looks at accumulating data are planned. Background theory and an application are presented. In
Autor:
ROBERT C. SCHRIVER
Publikováno v:
Pediatrics. 80:123-123
To the Editor.— My interest in the article by Rachelefsky et al (Pediatrics 1986;78:1133-1138) stems in part from the heightened media coverage it received. I must admit as a professional biostatistician that I have some difficulties with regard to